Explaining Clinical Trial Participation to Patients

The problem

Clinical trial participation is one of the most important conversations in oncology. Patients are often being offered a trial at a point when they have already absorbed an enormous amount of difficult information. The formal participant information sheet — required for ethical and regulatory reasons — is typically long, detailed, and written for legal compliance rather than patient comprehension.

Many patients arrive at the consent conversation having tried to read the information sheet and found it impenetrable. They sign because they trust you, not because they have genuinely understood. That is not informed consent. It is a patient who feels overwhelmed.

How AI helps

An AI tool can produce a plain-language summary of a trial's key features — what the trial is studying, what participation involves practically, what the main differences are from standard care, and what the patient's right to withdraw means. This is not a replacement for the official information sheet, which must be provided as required. It is a readable companion document that helps the patient understand the official one.

You give the tool the key features of the trial — in general, non-identifying terms. It drafts a plain-language explanation. You review for accuracy and add anything specific to your setting.

A real example

Dr Leila is a consultant clinical oncologist. She is seeing a patient in her early sixties who is being offered participation in a trial involving a novel immunotherapy agent alongside standard treatment. The patient has taken the information sheet home, tried to read it, and returned saying she found it confusing.

Dr Leila opens an AI tool and types:

Write a plain-language summary of what it means to take part in a clinical trial 
in oncology. The trial involves a new immunotherapy treatment given alongside 
standard chemotherapy, with some participants receiving the new treatment and some 
receiving standard treatment only (randomisation). The patient is a woman in her 
early sixties.

Cover:
- What a randomised clinical trial is, in simple terms
- What participation involves practically (extra visits, additional blood tests, 
  monitoring appointments)
- What randomisation means and that participants do not choose which group they 
  are in
- The right to withdraw at any time without affecting the rest of their care
- That the trial has ethical approval and that patient safety is monitored throughout

Do not include the trial name, specific drug names, or any clinical predictions. 
Tone: calm, clear, and respectful. Maximum 400 words.

The tool produces a plain-language document. Dr Leila reads it. The description of randomisation is clear and accurate. She adds one sentence clarifying that the trial is run by her institution and has been approved by the relevant ethics committee — which the tool correctly omitted as something she needed to specify herself. She gives the document to the patient alongside the official information sheet.

The patient returns for her consent appointment having read both. This time, she has questions — specific, considered questions about the monitoring visits and what happens if she wants to stop. Dr Leila considers this a significantly better consent conversation.

Try it yourself

Things to watch for

This document does not replace the official participant information sheet. Regulatory and ethical requirements for clinical trial consent are specific and non-negotiable. The plain-language summary is a supplementary aid, not a substitute.

Accuracy is your responsibility. The tool drafts based on what you describe. Any inaccuracy in your description of the trial will produce an inaccuracy in the document. Check every factual claim before giving it to a patient.

Randomisation can be difficult to explain without introducing anxiety. The tool's description of randomisation is usually accurate but occasionally produces phrasing that implies the patient is "missing out" on the new treatment if randomised to the control arm. Read this section carefully and adjust the framing if needed.

Cultural and language considerations matter. For patients where English is not the first language, or where trust in medical institutions is complicated, this plain-language summary may be a starting point that requires further translation or adaptation. The tool can produce a simpler version if you ask.

Remember: AI is a helpful assistant, not a clinician. You make the call.